Overview

Olema Oncology is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of targeted therapies for women’s cancers. Olema’s lead product candidate, OP-1250, a complete estrogen receptor (ER) antagonist (CERAN) and a selective ER degrader (SERD), is currently being studied in a Phase 1/2 clinical trial for the treatment of recurrent, metastatic or locally advanced ER-positive (ER+), human epidermal growth factor receptor 2-negative (HER2-) breast cancer. Olema is headquartered in San Francisco.

 

Latest Presentation

Stock Information

Data Provided by Refinitiv. Minimum 15 minutes delayed.

News Releases

23 Feb '2021
SAN FRANCISCO, Feb. 23, 2021 (GLOBE NEWSWIRE) -- Olema Pharmaceuticals, Inc. (“Olema” or “Olema Oncology,” NASDAQ: OLMA), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of targeted therapies for women’s cancers, today announced that it will

Events & Presentations

SEC Filings

Filing date Description Form

An amendment to the SC 13G filing

SC 13G/A

A statement of beneficial ownership of common stock by certain persons

SC 13G

A statement of beneficial ownership of common stock by certain persons

SC 13G